These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21172089)

  • 1. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry.
    Weigelt B; Reis-Filho JS
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S5. PubMed ID: 21172089
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics.
    Shiang C; Pusztai L
    Breast Cancer Res; 2010 Dec; 12 Suppl 4(Suppl 4):S6. PubMed ID: 21172090
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted sequencing may facilitate differential diagnostics of pulmonary tumours: a case series.
    Ericson-Lindquist K; Johansson A; Levéen P; Elmberger G; Jönsson G; Staaf J; Brunnström H
    Diagn Pathol; 2017 Mar; 12(1):31. PubMed ID: 28347348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.
    Viale G
    Breast; 2009 Oct; 18 Suppl 3():S32-6. PubMed ID: 19914539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing.
    Fusco N; Colombo PE; Martelotto LG; De Filippo MR; Piscuoglio S; Ng CK; Lim RS; Jacot W; Vincent-Salomon A; Reis-Filho JS; Weigelt B
    Histopathology; 2016 Jan; 68(2):262-71. PubMed ID: 25951887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions.
    Davidson B; Stavnes HT; Holth A; Chen X; Yang Y; Shih IeM; Wang TL
    J Cell Mol Med; 2011 Mar; 15(3):535-44. PubMed ID: 20132413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular detection of breast cancer markers.
    Verbanac KM
    Mol Diagn; 2001 Jun; 6(2):73-7. PubMed ID: 11468692
    [No Abstract]   [Full Text] [Related]  

  • 8. Breast tumour stroma is a prognostic indicator and target for therapy.
    Howell A; Landberg G; Bergh J
    Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S16. PubMed ID: 20030867
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene expression profiling of breast cancer: a new tumor marker.
    van't Veer LJ; Paik S; Hayes DF
    J Clin Oncol; 2005 Mar; 23(8):1631-5. PubMed ID: 15755970
    [No Abstract]   [Full Text] [Related]  

  • 10. [Gene expression profiling using cDNA arrays and prognosis of breast cancer].
    Bertucci F; Nasser V; Houlgatte R; Birnbaum D
    Bull Cancer; 2002 Jun; 89(6):571-4. PubMed ID: 12135856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular outlook.
    Caldas C; Aparicio SA
    Nature; 2002 Jan; 415(6871):484-5. PubMed ID: 11831227
    [No Abstract]   [Full Text] [Related]  

  • 12. Prediction of cancer outcome with microarrays.
    Goldhirsch A; Gelber RD; Viale G; Colleoni M; Coates AS
    Lancet; 2005 May 14-20; 365(9472):1685-6; author reply 1686. PubMed ID: 15894095
    [No Abstract]   [Full Text] [Related]  

  • 13. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular profiling of breast cancer: clinical implications.
    Cleator S; Ashworth A
    Br J Cancer; 2004 Mar; 90(6):1120-4. PubMed ID: 15026788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.
    Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL
    BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy.
    Baehner FL; Lee M; Demeure MJ; Bussey KJ; Kiefer JA; Barrett MT
    J Surg Oncol; 2011 May; 103(6):563-73. PubMed ID: 21480251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of differentially expressed genes in an isogenic breast metastasis model using RNA arbitrarily primed-polymerase chain reaction coupled with array hybridization (RAP-array).
    Sloan DD; Nicholson B; Urquidi V; Goodison S
    Am J Pathol; 2004 Jan; 164(1):315-23. PubMed ID: 14695344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic gene signatures and emerging novel prognostic tests in the management of early stage breast cancer.
    Tordai A; Liedtke C; Pusztai L
    Clin Exp Metastasis; 2009; 26(7):625-32. PubMed ID: 19381845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple gene signatures aim to qualify risk in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2005 Mar; 97(5):332. PubMed ID: 15741566
    [No Abstract]   [Full Text] [Related]  

  • 20. MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology.
    Mittempergher L; Delahaye LJMJ; Witteveen AT; Spangler JB; Hassenmahomed F; Mee S; Mahmoudi S; Chen J; Bao S; Snel MHJ; Leidelmeijer S; Besseling N; Bergstrom Lucas A; Pabón-Peña C; Linn SC; Dreezen C; Wehkamp D; Chan BY; Bernards R; van 't Veer LJ; Glas AM
    J Mol Diagn; 2019 Sep; 21(5):808-823. PubMed ID: 31173928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.